FR2101191B1 - - Google Patents

Info

Publication number
FR2101191B1
FR2101191B1 FR7128227A FR7128227A FR2101191B1 FR 2101191 B1 FR2101191 B1 FR 2101191B1 FR 7128227 A FR7128227 A FR 7128227A FR 7128227 A FR7128227 A FR 7128227A FR 2101191 B1 FR2101191 B1 FR 2101191B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR7128227A
Other versions
FR2101191A1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Co
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of FR2101191A1 publication Critical patent/FR2101191A1/fr
Application granted granted Critical
Publication of FR2101191B1 publication Critical patent/FR2101191B1/fr
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR7128227A 1970-08-03 1971-08-02 Expired FR2101191B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6062170A 1970-08-03 1970-08-03

Publications (2)

Publication Number Publication Date
FR2101191A1 FR2101191A1 (fr) 1972-03-31
FR2101191B1 true FR2101191B1 (fr) 1975-02-07

Family

ID=22030682

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7128227A Expired FR2101191B1 (fr) 1970-08-03 1971-08-02

Country Status (9)

Country Link
US (1) US3773955A (fr)
AU (1) AU463074B2 (fr)
BE (1) BE770625A (fr)
DE (1) DE2138593A1 (fr)
DK (1) DK133035B (fr)
FR (1) FR2101191B1 (fr)
GB (1) GB1353815A (fr)
NL (1) NL7109388A (fr)
ZA (1) ZA714683B (fr)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3885027A (en) * 1971-04-12 1975-05-20 West Laboratories Inc Orally administered drug composition for therapy in the treatment of narcotic drug addiction
US3896226A (en) * 1971-11-26 1975-07-22 Lewinstein Evalina 6-methylene-6-desoxy dihydro morphine and codeine derivatives and pharmaceutically acceptable salts thereof, and use of the same as a narcotic antagonist
US3906100A (en) * 1973-05-24 1975-09-16 Miles Lab N-benzyl-N-{8 2-phenyl-2-(4-phenyl-1-piperidyl)-ethyl{9 -propionamide para-chlorobenzene sulfonate
US4048316A (en) * 1974-03-04 1977-09-13 Penn Nathar W Composition for antagonizing the narcotic effects of barbiturate addiction and withdrawal effects, and for treatment of barbiturate poisoning
US4126684A (en) * 1976-02-11 1978-11-21 Ciba-Geigy Corporation 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
JPS56128715A (en) * 1980-03-06 1981-10-08 Bristol Myers Co Analgesic abuse prevention
US4366159A (en) * 1981-09-08 1982-12-28 Michael Richard Magruder Nalbuphine-narcotic analgesic composition and method of producing analgesia
DE3216327C1 (de) * 1982-05-03 1983-05-19 Siempelkamp Gießerei GmbH & Co, 4150 Krefeld Herstellung von dickwandigen Abschirmtransport- und Lagerbehältern aus sphärolitischem Gußeisen
WO1984000889A1 (fr) * 1982-08-25 1984-03-15 Joel E Bernstein Methode et medicament de traitement du prurit
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4888346A (en) * 1986-10-07 1989-12-19 Bernard Bihari Method for the treatment of persons infected with HTLV-III (AIDS) virus
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
ES2120451T7 (es) 1991-09-06 2009-11-05 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Composicion que comprende un compuesto de tramadol y acetaminofeno, y su uso.
US7027859B1 (en) 1994-09-26 2006-04-11 Alza Corporation Electrotransport delivery device having improved safety and reduced abuse potential
US5587381A (en) * 1995-03-27 1996-12-24 Sinclair; John D. Method for terminating methadone maintenance through extinction of the opiate-taking responses
AU773642C (en) 1997-12-22 2006-04-06 Mundipharma Pty Limited Opioid agonist/antagonist combinations
CN1204890C (zh) 1997-12-22 2005-06-08 欧罗赛铁克股份有限公司 防止阿片样物质滥用的方法
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
EP1206264A2 (fr) * 1999-08-25 2002-05-22 Barrett R. Cooper Compositions et procedes permettant de traiter l'intolerance aux opiaces
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
JP2003522144A (ja) 2000-02-08 2003-07-22 ユーロ−セルティーク,エス.エイ. オピオイドアゴニストおよびアンタゴニストを含む制御放出組成物
EP1387673B1 (fr) 2001-05-11 2010-12-29 Endo Pharmaceuticals Inc. Forme posologique d'opioides a liberation prolongee empechant la consommation abusive
CA2778114A1 (fr) * 2001-05-11 2002-11-21 Endo Pharmaceuticals, Inc. Forme posologique d'opioides empechant la consommation abusive
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
WO2003002100A1 (fr) * 2001-06-26 2003-01-09 Farrell John J Systeme d'administration de narcotique inviolable
ES2319620T3 (es) 2001-07-18 2009-05-11 Euro-Celtique S.A. Conbinaciones farmaceuticas de oxicodona y naloxona.
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
SI1414451T1 (sl) 2001-08-06 2009-10-31 Euro Celtique Sa Formulacije opioidnega agonista s sproščanja sposobnim in sekvestriranim antagonistom
US20030068276A1 (en) * 2001-09-17 2003-04-10 Lyn Hughes Dosage forms
US20040126428A1 (en) * 2001-11-02 2004-07-01 Lyn Hughes Pharmaceutical formulation including a resinate and an aversive agent
ES2733044T1 (es) * 2002-04-05 2019-11-27 Mundipharma Pharmaceuticals S L Composición farmacéutica que contiene oxicodona y naloxona
US20030199439A1 (en) * 2002-04-22 2003-10-23 Simon David Lew Compositions of alpha3beta4 receptor antagonists and opioid agonist analgesics
AR039336A1 (es) * 2002-04-23 2005-02-16 Alza Corp Sistemas analgesicos transdermicos con potencial de abuso reducido
US8840928B2 (en) * 2002-07-05 2014-09-23 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US10004729B2 (en) 2002-07-05 2018-06-26 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
EP1594467A4 (fr) * 2002-07-05 2008-10-22 Collegium Pharmaceutical Inc Compositions pharmaceutiques d'opioides et d'autres medicaments empechants les utilisations abusives
US8557291B2 (en) * 2002-07-05 2013-10-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
EP2422775A3 (fr) * 2002-09-20 2012-04-18 Alpharma, Inc. Séquestration de sous-unité et compositions et procédés associés
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
TWI347201B (en) 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
EP1615625A4 (fr) 2003-04-21 2010-12-15 Euro Celtique Sa Forme posologique inviolable contenant des particules co-extrudees d'agent repulsif contraire et procede de fabrication
RS20050812A (en) 2003-04-30 2007-12-31 Purdue Pharma L.P., Tamper resistant transdermal dosage form
US20040219195A1 (en) * 2003-04-30 2004-11-04 3M Innovative Properties Company Abuse-resistant transdermal dosage form
US7182955B2 (en) * 2003-04-30 2007-02-27 3M Innovative Properties Company Abuse-resistant transdermal dosage form
US8790689B2 (en) * 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
CA2529984C (fr) 2003-06-26 2012-09-25 Isa Odidi Capsules contenant un inhibiteur de la pompe a protons comprenant des unites secondaires differemment structurees permettant une liberation retardee de l'ingredient actif
WO2005044243A2 (fr) * 2003-10-30 2005-05-19 Alza Corporation Systemes analgesiques transdermiques reduisant les risques d'abus de consommation
US8883204B2 (en) 2003-12-09 2014-11-11 Purdue Pharma L.P. Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
SI1691892T1 (sl) * 2003-12-09 2007-08-31 Euro Celtique Sa Varnostna koekstrudirana dozirna oblika, ki vsebuje aktivno sredstvo in protisredstvo, in postopek njene izdelave
JP2007526796A (ja) * 2003-12-15 2007-09-20 アレックザ ファーマシューティカルズ, インコーポレイテッド 薬剤エアロゾル吸入による突出痛の治療
US20050165038A1 (en) * 2004-01-22 2005-07-28 Maxwell Gordon Analgetic dosage forms that are resistant to parenteral and inhalation dosing and have reduced side effects
CA2557839C (fr) * 2004-03-30 2011-05-10 Euro-Celtique S.A. Forme posologique resistant aux violations, comprenant un absorbant et un agent adverse
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
EP1604667A1 (fr) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioides pour le traitement des impatiences des membres inférieurs
EP1604666A1 (fr) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioides pour le traitement de la bronchopneumopathie chronique obstructive
HUE037643T2 (hu) 2004-06-12 2018-09-28 Collegium Pharmaceutical Inc Visszaélésre nem alkalmas gyógyszerkészítmények
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
KR20070053267A (ko) * 2004-08-20 2007-05-23 쓰리엠 이노베이티브 프로퍼티즈 컴파니 반투명 보호 필름을 갖는 경피 약물 전달 장치
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
EP3228308A1 (fr) * 2005-01-28 2017-10-11 Euro-Celtique S.A. Formes posologiques résistantes à l'alcool
TW200640526A (en) * 2005-02-24 2006-12-01 Alza Corp Transdermal electrotransport drug delivery systems with reduced abuse potential
EP1702558A1 (fr) 2005-02-28 2006-09-20 Euro-Celtique S.A. Procédé et dispositif pour évaluer la fonction de l'activité intestinale
EP1695700A1 (fr) 2005-02-28 2006-08-30 Euro-Celtique S.A. Forme posologique contenant de l'oxycodone et de la naloxone
EP1895995A2 (fr) * 2005-05-13 2008-03-12 Alza Corporation Systeme d'administration de galantamine a couches multiples equipe d'une protection contre l ecoulement un flux de matiere de reservoir
WO2006133102A2 (fr) * 2005-06-03 2006-12-14 Trans-Dermal Patents Company, Llc Systeme d'administration d'agent et ses utilisations
US20090143761A1 (en) * 2005-06-03 2009-06-04 Transdermal Patents Company, Llc Agent delivery system and uses of same
WO2007056142A2 (fr) * 2005-11-02 2007-05-18 Theraquest Biosciences, Llc Procedes de prevention du syndrome serotoninergique et compositions utilisees a cette fin
US9125833B2 (en) * 2005-11-02 2015-09-08 Relmada Therapeutics, Inc. Multimodal abuse resistant and extended release opioid formulations
US20090082466A1 (en) * 2006-01-27 2009-03-26 Najib Babul Abuse Resistant and Extended Release Formulations and Method of Use Thereof
US8329744B2 (en) * 2005-11-02 2012-12-11 Relmada Therapeutics, Inc. Methods of preventing the serotonin syndrome and compositions for use thereof
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
EP1810670A1 (fr) * 2006-01-19 2007-07-25 Holger Lars Hermann Combinaison de Polamidone et de Naloxone dans le traitement de la toxicomanie
FR2898056B1 (fr) 2006-03-01 2012-01-20 Ethypharm Sa Comprimes resistant a l'ecrasement destines a eviter le detournement illicite
EP2007360B1 (fr) 2006-04-03 2014-11-26 Isa Odidi Dispositif d'administration à libération commandée comprenant un enrobage organosol
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US20070278289A1 (en) * 2006-05-31 2007-12-06 Toshiba Tec Kabushiki Kaisha Payment adjusting apparatus and program therefor
CA2655835C (fr) 2006-06-19 2015-07-21 Alpharma, Inc. Compositions pharmaceutiques d'agonistes opioides resistants a l'abus
EP1897543A1 (fr) 2006-08-30 2008-03-12 Euro-Celtique S.A. Gaufre de buprénorphine pour la thérapie de substitution
ES2594867T3 (es) 2007-03-09 2016-12-23 Alexza Pharmaceuticals, Inc. Unidad de calentamiento para usar en un dispositivo de administración de fármaco
US7748244B2 (en) * 2007-09-14 2010-07-06 Schlage Lock Company Deadbolt lock assembly
WO2009059048A2 (fr) * 2007-10-30 2009-05-07 The Regents Of The University Of Colorado Opioïdes-(+) et méthodes d'utilisation
US20100239523A1 (en) * 2007-10-30 2010-09-23 The Regents Of The University Of Colorado Tlr modulators and methods for using the same
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
UY32487A (es) 2009-03-10 2010-06-30 Euro Celtique Sa Composiciones farmacéuticas de liberación inmediata comprendiendo oxicodona y naloxona
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
CA2827273A1 (fr) 2011-02-17 2012-08-23 QRxPharma Ltd. Technologie pour prevenir l'abus de formes pharmaceutiques solides
UA116567C2 (uk) 2013-07-23 2018-04-10 Євро-Селтік С.А. Комбінація оксикодону та налоксону для застосування в лікуванні болю у пацієнтів, які страждають від болю та захворювання, що призводить до дисбактеріозу кишечнику та/або підвищує ризик кишкової бактеріальної транслокації
AU2016101552A4 (en) 2015-09-03 2016-10-13 Acino Pharma Ag Reduction of the deallylation of naloxone during the storage of a naloxone-containing retard formulation
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
US10532385B2 (en) 2016-06-29 2020-01-14 Disposerx, Inc. Disposal of medicaments

Also Published As

Publication number Publication date
BE770625A (fr) 1972-01-28
FR2101191A1 (fr) 1972-03-31
DE2138593A1 (de) 1972-03-30
DK133035B (da) 1976-03-15
NL7109388A (fr) 1972-02-07
US3773955A (en) 1973-11-20
GB1353815A (en) 1974-05-22
ZA714683B (en) 1972-04-26
AU463074B2 (en) 1975-07-17
AU3185671A (en) 1973-02-01

Similar Documents

Publication Publication Date Title
FR2101191B1 (fr)
AR204384A1 (fr)
ATA96471A (fr)
AU2044470A (fr)
AU1146470A (fr)
AU1473870A (fr)
FR2113984B1 (fr)
AU1326870A (fr)
AU2085370A (fr)
AU2130570A (fr)
AU1064870A (fr)
AU1086670A (fr)
AU2131570A (fr)
AU2144270A (fr)
AU2274770A (fr)
AU2130770A (fr)
AU2119370A (fr)
ATA672271A (fr)
AU2115870A (fr)
AU1328670A (fr)
AU1277070A (fr)
AU1247570A (fr)
AU1235770A (fr)
AU1004470A (fr)
AU2112570A (fr)

Legal Events

Date Code Title Description
ST Notification of lapse